2Hagen PT, Scholz DG, Edwards WD. Incidence and size of patent foramen ovale during the in, st 10 decades of life:an autopsy study of 965 normal hearts[ J]. Mayo Clin Proc, 1984, 59( 1 ) :17 - 20.
3Furlan A J, Reisman M, Massaro J, et al. Closure or medical therapy for cryptogenic stroke with patent foramen ovale[ J]. N Engl J Med, 2012, 356( 11 ) :991 - 999.
4Carroll JD, Saver JL, Thaler DE, et al. Closure of patent foramen ovale versus medical therapy after cryptogenic stroke [ J ]. N Engl J Med, 2015, 568 (12) :1092 - 1100.
5Meier B, Kalesan B, Mattle HP, et al. Percutaneous closure of pa- tent foramen ovale in cryptogenic embolism [ J ]. N Engl J Med, 2013, 368(12) :1083 - 1091.
7Mohr JP, Thompson JL, Lazar RM, et al. comparison of warfarin and aspirin for the prevention of recurrent ischemic stroke [ J ]. N Engl J Med, 2001, 345(20) :1444 - 1451.
8Bogousslavsky J, Garazi S, Jeanrenaud X, et al. Stroke recurrence in patients with patent foramen ovale:the Lausanne Study. Lausanne Stroke with Paradoxal Embolism Study Group[ J]. Neurology, 1996, 46 (5) : 1301 - 1305.
9Homma S, Saeco RL, Di Tullio MR, et al. Effect of medical treat- ment in stroke patients with patent foramen ovale: patent foramen ovale in Cryptogenic Stroke Study [ J ]. Circulation, 2002, 105 (22) :2625 -2631.
10Cujec B, Mainra R, Johnson DH. Prevention of recurrent cerebral ischemic events in patients with patent foramen ovale and cryptogenic strokes or transient ischemic attacks [ J]. Can J Cardiol, 1999, 15 (1) :57 -64.
